Flow diagram of the patient selection into the final analysis. by Zi-Rong Chen (9227618)

Subjects:

Demographic information of study participants. Demographic information of participants in school-based and household-based cross-sectional surveys of the SchistoBreak study impleme... by Lydia Trippler (10136316)

Subjects:

S2 Data - Adaptive integrated intervention approaches for schistosomiasis elimination in Pemba: A 4-year intervention study and focus on hotspots by Lydia Trippler (10136316)

Subjects:

Patients’ demographics and clinical parameters. by Zi-Rong Chen (9227618)

Subjects:

Characteristics of households participating in the SchistoBreak study in Pemba, Tanzania. by Lydia Trippler (10136316)

Subjects:

Development and Use of a Galectin-1-Specific Nanobody for Tumor Imaging and Elucidating the Role of Galectin‑1 in Cancer by Philippine Granger Joly de Boissel (21688159)

Subjects:

<i>Schistosoma haematobium</i> prevalence in hotspot implementation units (IUs) in annual school-based surveys (A) and household-based surveys (B) of the SchistoBreak study in Pemb... by Lydia Trippler (10136316)

Subjects:

Table 2 - Early identification of the efficacy of 0.125% atropine treatment for children with Myopia: A prospective pilot study by Zi-Rong Chen (9227618)

Subjects:

<i>Schistosoma haematobium</i> and microhematuria prevalence. by Lydia Trippler (10136316)

Subjects:

Annual change in low-prevalence (orange) and hotspot (red) implementation units (IUs). by Lydia Trippler (10136316)

Subjects:

Chance of infection with <i>Schistosoma haematobium.</i> by Lydia Trippler (10136316)

Subjects:

Study participation. by Lydia Trippler (10136316)

Subjects:

Microhematuria prevalence in hotspot implementation units. by Lydia Trippler (10136316)

Subjects:

Interventions in the hotspot implementation units (IUs). Interventions in the hotspot IUs of the SchistoBreak study in three intervention periods in Pemba, Tanzania, from 2021 to 2... by Lydia Trippler (10136316)

Subjects:

Correlation analysis, Data show only the values of the correlations that were significant (p < 0.05). by Glaucia Vilar-Pereira (686134)

a-d. Difference in (a) probing depth; (b) clinical attachment level; (c) bleeding on probing, and (d) plaque index values between baseline and six months after treatment using syst... by Iva Milinkovic (22331710)

Subjects:

Immunogenicity results of different vaccination schemes at different time points. by Rima Moghnieh (679199)

Subjects:

LDH expression is a surrogate for cell death. by Bryan S. Margulies (21492667)

Subjects:

Effectiveness of the available COVID-19 primary and booster vaccination schemes against laboratory-confirmed infections during the different waves. by Rima Moghnieh (679199)

Subjects:

Diagrammatic illustration showing the time-course of the experimental set-up as well as the experimental endpoints. by Bryan S. Margulies (21492667)

Subjects: